OncoMatch/Clinical Trials/NCT06557421
De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients
Is NCT06557421 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Venetoclax and Azacitidine for acute myeloid leukemia.
Treatment: Venetoclax · Azacitidine — The goal of this clinical trial is to test efficacy and safety of a VENETOCLAX-AZACITIDINE (VEN-AZA) de-escalation strategy in Acute Myeloid Leukemia responding patients. The main objectives of the study are: * Evaluation of the efficacy of VEN-AZA de-escalation strategy by measuring the effect of VEN-AZA discontinuation in term of Disease-Free Survival. * Evaluation of the other efficacy parameters and safety of VEN-AZA de-escalation strategy. Patients from the prospective study will be compared to a retrospective cohort of patients who will be selected on the basis of identical eligibility criteria. Participants will: * Stop VEN-DASA treatment * Be closely monitored by regular evaluation of the disease
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: venetoclax and azacitidine (venetoclax, azacitidine) — first-line
VEN-AZA given as first-line treatment; Duration of VEN-AZA therapy of 12 months (+/- 28 days), regardless of duration of VEN-AZA cycles and the doses
Cannot have received: venetoclax and azacitidine (venetoclax, azacitidine)
VEN-AZA given as salvage therapy
Cannot have received: allogeneic stem cell transplant
Prior allogeneic stem cell transplant
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify